Spun Out, Covidien Rolls On
Executive Summary
Covidien, nearly a year removed from spinning out of scandal-plagued parent Tyco International, is pushing forward as an independent company. Covidien execs are investing in new product creation, sales and marketing efforts, and acquisitions. That means Covidien is about to make a big splash in the device industry, with devices bringing in two-thirds of this ambitious company's revenues.
You may also be interested in...
Covidien’s Mallinckrodt To Buy CNS Therapeutics For $100M
Covidien’s pharmaceutical arm Mallinckrodt has announced its plans to acquire St. Paul, MN-based CNS Therapeutics for $100 million. The acquisition will complement Mallinckrodt’s own generic pain therapeutic offerings. Mallinckrodt is on track to be spun out of Covidien in mid-2013.
Covidien Runs Familiar But Different Plays to Build Vascular Franchise
Covidien Ltd. continues to build its vascular global business unit with the acquisition of peripheral leader ev3 Inc.
Covidien Runs Familiar But Different Plays to Build Vascular Franchise
Covidien Ltd. continues to build its vascular global business unit with the acquisition of peripheral leader ev3 Inc.